Highlights from HemOncToday Melanoma and Cutaneous Malignancies

Status of injectable therapy in metastatic melanoma

  • March 27, 2013

NEW YORK – In this video, Robert H.I. Andtbacka, MD, CM, spotlights newly available injectable therapies for the treatment of melanoma at the HemOnc Today Melanoma and Cutaneous Malignancies symposium – in particular, using plasmas and viruses to inject therapies directly into a tumor, resulting in a local immune response against melanoma at the injection site.

Andtbacka also discusses the release of new phase III trial data in which talimogene laherparepvec (TVEC) met its primary endpoint by significantly reducing tumors in 16% of melanoma patients for at least six months vs. only 2% in a control cohort.